<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="epco-gdp-rrlbcl-modi">
    <meta name="study:title" content="PS1979 - Epcoritamab with gemcitabine, dexamethasone, and cisplatin (Epco-GDP) in relapsed refractory large B-cell lymphoma- An interim analysis of Phase II multicenter investigated-initiated trial">
    <meta name="study:fileName" content="Abstracts/EPCO-GDP-RRLBCL-MODI-PS1979.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Epcoritamab,Bispecific antibodies,Gemcitabine,Dexamethasone,Cisplatin,Chemotherapy,Anti-CD20 antibody,CAR-T cell therapy,Autologous Stem Cell Transplant">

    <title>PS1979: Epco-GDP in R/R LBCL (Interim Analysis) (Modi) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1979 - Epcoritamab + GDP (Epco-GDP) in R/R LBCL (Phase II Interim Analysis)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=14 enrolled)</h4>
                    <p>RR LBCL Pts (≥1 prior LOT), eligible for CAR T/SCT. Aim: Evaluate safety & efficacy of Epco-GDP as bridge/salvage.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Epco-GDP, 3 Cycles)</h4>
                    <p>Epco SC (step-up C1, then weekly) + GDP (Gem, Cis, Dexa). Outpatient. Then CAR T/SCT or Epco mono.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Post 3x Epco-GDP, N=14)</h4>
                    <p>ORR: <span class="highlight-value">78.6%</span>, CR Rate: <span class="highlight-value">64.3%</span>. 6-mo DOR 100%, PFS 73.9%, OS 100% (mF/U 7.7mo).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>CRS 50% (all G1-2), no ICANS. Manageable AEs (Thrombocytopenia G3/4 85.7%). Early efficacy signal, feasible outpatient bridge.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1979 - Epcoritamab with gemcitabine, dexamethasone, and cisplatin (Epco-GDP) in relapsed refractory large B-cell lymphoma- An interim analysis of Phase II multicenter investigated-initiated trial</h1>
            <p class="abstract-sub-header">Dipenkumar Modi, Vy Ong, Seongho Kim, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1979 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Patients (pts) with primary refractory or relapsed large B-cell lymphoma (LBCL) receive CAR T-cell or autologous stem cell transplant (SCT) as curative therapy.</li>
                        <li>Rapidly progressing, symptomatic pts often need bridging treatment while awaiting CAR T-cell therapy.</li>
                        <li>Salvage/Bridging chemotherapy with high response rates is warranted.</li>
                        <li>Epcoritamab (CD3xCD20 bispecific antibody) is approved for relapsed/refractory (RR) LBCL after ≥2 prior lines of therapy.</li>
                        <li>Hypothesis: Epcoritamab + Gemcitabine, Dexamethasone, Cisplatin (Epco-GDP) improves outcomes in RR LBCL eligible for CAR T/SCT.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the safety and efficacy of the Epco-GDP regimen in RR LBCL patients.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Trial Type: Phase II multicenter investigator-initiated trial (interim analysis).</li>
                        <li>Patient Population: CD20+ RR LBCL, ≥1 prior line of therapy (including anti-CD20 Ab), eligible for CAR T-cell or SCT.</li>
                        <li>Treatment Regimen (Epco-GDP, 3 cycles, outpatient, 21-day cycles):
                            <ul class="list-circle list-inside ml-4">
                                <li>Epcoritamab (Epco) SC: C1 weekly step-up (0.16mg, 0.8mg, 48mg); C2 onwards weekly 48mg.</li>
                                <li>GDP: Gemcitabine 1000 mg/m² (Days 1, 8); Cisplatin 75 mg/m² (Day 1); Dexamethasone 40mg PO (Days 1-4).</li>
                            </ul>
                        </li>
                        <li>Post C3: Pts could proceed to CAR T/SCT per investigator discretion. Those not proceeding could receive Epco monotherapy (6 additional 28-day cycles, C4-C9) or until toxicity/PD.</li>
                        <li>Primary Objective: Complete Remission (CR) rate per Lugano criteria after 3 cycles.</li>
                        <li>Data Cutoff: November 30, 2024.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Epco-GDP Phase II Trial Design (Interim)</h3>
                        <div class="schema-enrollment">
                            <strong>RR LBCL Pts (N=14 Enrolled)</strong>
                            <span>CD20+, ≥1 Prior LOT, Eligible for CAR T/SCT</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-blue-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Epco-GDP (3 Cycles, Outpatient)</strong>
                                <span>Epcoritamab SC (C1 step-up, then weekly)</span>
                                <span>+ GDP (Gemcitabine, Dexamethasone, Cisplatin)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                             <div class="schema-phase cohort-a" style="flex-basis: 48%;">
                                <strong>Consolidation Option 1</strong>
                                <span>Proceed to CAR T-cell or SCT</span>
                                <span>(per Investigator Discretion)</span>
                            </div>
                             <div class="schema-phase cohort-b" style="flex-basis: 48%;">
                                <strong>Consolidation Option 2</strong>
                                <span>Epcoritamab Monotherapy</span>
                                <span>(6 additional cycles, C4-C9)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Primary EP: CR Rate (post C3 Epco-GDP)</span>
                           <span>Secondary EPs: ORR, DOR, PFS, OS, Safety</span>
                           <span>Feasibility of cell collection</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=14)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 63 years (range, 43-72).</li>
                        <li>Stage IV Disease: 86%.</li>
                        <li>DLBCL, NOS Subtype: 86%.</li>
                        <li>Double Expressor Lymphoma: 21%.</li>
                        <li>Double Hit Lymphoma: 7%.</li>
                        <li>Primary Refractory Disease: 43%.</li>
                        <li>Median Prior Lines of Therapy: 2 (range, 1-4).</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Interim Analysis, N=14)</h2>
                    <p class="text-sm mb-1">All patients received 3 cycles of Epco-GDP.</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Overall Response Rate (ORR): 78.6%</strong></li>
                        <li><strong>Complete Remission (CR) Rate: 64.3%</strong></li>
                    </ul>
                    <div class="chart-container my-4">
                        <svg id="epcoGdpResponseChart" width="350" height="280"></svg>
                        <div id="epcoGdpResponseLegend" class="legend"></div>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-3">
                        <li>Successful stem cell mobilization or T-lymphocyte collection in all patients.</li>
                        <li>Post-study treatment: 8 underwent autologous SCT, 5 underwent CAR T-cell therapy.</li>
                        <li>Median follow-up for survival: 7.7 months (95% CI, 6 to 10.6).</li>
                        <li>At 6-months:
                            <ul class="list-circle list-inside ml-4">
                                <li>Duration of Response (DOR): 100%.</li>
                                <li>Progression-Free Survival (PFS): 73.9%.</li>
                                <li>Overall Survival (OS): 100%.</li>
                            </ul>
                        </li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=14)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Cytokine Release Syndrome (CRS): 7 (50%) pts, all Grade 1-2.</li>
                        <li>No ICANS observed.</li>
                        <li>Hospitalization for CRS or fever: 17%.</li>
                        <li><strong>Adverse Events (AEs) in ≥20% of pts (any grade):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Thrombocytopenia: 92.9%</li>
                                <li>Anemia: 71.4%</li>
                                <li>Neutropenia: 50%</li>
                                <li>Nausea: 42.9%</li>
                                <li>Acute Kidney Injury (AKI): 28.6%</li>
                                <li>Febrile Neutropenia: 21.4%</li>
                                <li>Diarrhea: 21.4%</li>
                                <li>Tinnitus: 28.6%</li>
                                <li>AST elevation: 28.6%</li>
                                <li>ALT elevation: 50%</li>
                                <li>ALP elevation: 28.6%</li>
                            </ul>
                        </li>
                         <li><strong>Grade 3-4 AEs in ≥20% of pts:</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Thrombocytopenia: 85.7%</li>
                                <li>Anemia: 50%</li>
                                <li>Neutropenia: 35.7%</li>
                                <li>AKI: 21.4%</li>
                                <li>Febrile Neutropenia: 21.4%</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The Epco-GDP regimen shows an early signal of efficacy in RR LBCL, with high ORR and CR rates after 3 cycles.</li>
                <li>This regimen is feasible to administer in the outpatient setting as a bridge or salvage therapy prior to CAR T-cell therapy or SCT.</li>
                <li>Epco-GDP did not adversely impact stem cell mobilization or T-lymphocyte collection.</li>
                <li>The safety profile, including CRS and hematologic AEs, appears manageable.</li>
                <li>The study is continuing enrollment towards a final accrual goal of 32 patients.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>Ab, Antibody; AE, Adverse Event; AKI, Acute Kidney Injury; ALP, Alkaline Phosphatase; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; CAR T, Chimeric Antigen Receptor T-cell; C, Cycle; CD, Cluster of Differentiation; CI, Confidence Interval; CR, Complete Remission; CRS, Cytokine Release Syndrome; D, Day; Dexa, Dexamethasone; DLBCL, Diffuse Large B-Cell Lymphoma; DOR, Duration of Response; EP, Endpoint; Epco, Epcoritamab; F/U, Follow-up; G, Grade; GDP, Gemcitabine, Dexamethasone, Cisplatin; Gem, Gemcitabine; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; IIT, Investigator-Initiated Trial; LBCL, Large B-Cell Lymphoma; LOT, Lines of Therapy; m, Median; mg/m², Milligrams per square meter; NOS, Not Otherwise Specified; ORR, Overall Response Rate; OS, Overall Survival; PFS, Progression-Free Survival; Ph, Phase; PO, Per Os (by mouth); Pts, Patients; RR, Relapsed Refractory; SC, Subcutaneous; SCT, Stem Cell Transplant.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Modi D, Ong V, Kim S, et al. Epcoritamab with gemcitabine, dexamethasone, and cisplatin (Epco-GDP) in relapsed refractory large B-cell lymphoma- An interim analysis of Phase II multicenter investigated-initiated trial. Abstract #PS1979 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1979 | Abstract Release: 05/14/25 | Presentation: 06/14/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
    function drawEpcoGdpResponseChart(containerId, legendContainerId) {
        const chartTitle = "Response to Epco-GDP (N=14, Post 3 Cycles)";
        // ORR 78.6%, CRR 64.3%. PRR = ORR - CRR = 78.6 - 64.3 = 14.3%
        const chartData = [
            { response: "CR", rate: 64.3, color: "var(--sobi-teal)" },
            { response: "PR", rate: 14.3, color: "var(--sobi-light-teal-bg)" }
            // Other responses (SD, PD) not explicitly broken down for all 14 in this section, ORR is the sum.
        ];
        const orrRate = chartData.reduce((sum, item) => sum + item.rate, 0);


        const svg = d3.select(containerId);
        const legendContainer = d3.select(legendContainerId);
        svg.selectAll("*").remove();
        legendContainer.selectAll("*").remove();

        let containerWidth = 350;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 280);
        }
        
        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 60, right: 20, bottom: 50, left: 50 }; // Increased top for ORR text
        const chartWidth = svgWidth - margin.left - margin.right;
        const chartHeight = svgHeight - margin.top - margin.bottom;

        if (chartWidth <= 0 || chartHeight <=0) return;

        const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);

        const xScale = d3.scaleBand()
            .domain(chartData.map(d => d.response))
            .range([0, chartWidth])
            .padding(0.4); // Wider padding for fewer bars

        const yScale = d3.scaleLinear()
            .domain([0, 100]) // Percentage
            .range([chartHeight, 0]);

        g.append("g")
            .attr("transform", `translate(0,${chartHeight})`)
            .call(d3.axisBottom(xScale))
            .selectAll("text")
            .attr("class", "axis-text")
            .style("font-size", "10px")
            .attr("transform", "translate(0,5)");

        g.append("g")
            .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
            .selectAll("text")
            .attr("class", "axis-text")
            .style("font-size", "10px");
        
        g.append("text")
            .attr("transform", "rotate(-90)")
            .attr("y", 0 - margin.left + 10)
            .attr("x", 0 - (chartHeight / 2))
            .attr("dy", "1em")
            .style("text-anchor", "middle")
            .attr("class", "axis-label")
            .text("Response Rate (%)");

        g.append("g").attr("class", "grid")
            .call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
            .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

        g.selectAll(".bar")
            .data(chartData)
            .enter().append("rect")
            .attr("class", "bar")
            .attr("x", d => xScale(d.response))
            .attr("y", d => yScale(d.rate))
            .attr("width", xScale.bandwidth())
            .attr("height", d => chartHeight - yScale(d.rate))
            .attr("fill", d => d.color)
            .attr("rx", 3).attr("ry", 3);

        g.selectAll(".bar-label")
            .data(chartData)
            .enter().append("text")
            .attr("class", "chart-label")
            .attr("x", d => xScale(d.response) + xScale.bandwidth() / 2)
            .attr("y", d => yScale(d.rate) - 5)
            .attr("text-anchor", "middle")
            .style("font-size", "10px")
            .style("fill", "var(--sobi-dark-text)")
            .text(d => `${d.rate.toFixed(1)}%`);
        
        svg.append("text")
            .attr("x", svgWidth / 2)
            .attr("y", margin.top / 2 - 5) 
            .attr("text-anchor", "middle")
            .style("font-size", "13px")
            .style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)")
            .text(chartTitle);
        
        svg.append("text")
            .attr("x", svgWidth / 2)
            .attr("y", margin.top / 2 + 15) 
            .attr("text-anchor", "middle")
            .style("font-size", "11px")
            .style("font-weight", "bold")
            .style("fill", "var(--sobi-teal-darker)") // A distinct color for ORR
            .text(`Overall Response Rate (ORR): ${orrRate.toFixed(1)}%`);

        const legendItems = legendContainer.selectAll(".legend-item")
            .data(chartData).enter().append("div").attr("class", "legend-item");
        legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
        legendItems.append("span").text(d => d.response);
    }
    
    function debounce(func, wait) {
        let timeout;
        return function executedFunction(...args) {
            const later = () => { clearTimeout(timeout); func(...args); };
            clearTimeout(timeout);
            timeout = setTimeout(later, wait);
        };
    };

    const debouncedDrawEpcoGdpChart = debounce(() => drawEpcoGdpResponseChart("#epcoGdpResponseChart", "#epcoGdpResponseLegend"), 250);
    
    window.addEventListener('resize', debouncedDrawEpcoGdpChart);
    document.addEventListener('DOMContentLoaded', debouncedDrawEpcoGdpChart);
    if (document.readyState === "complete" || document.readyState === "interactive") {
         setTimeout(debouncedDrawEpcoGdpChart, 0); 
    }
    </script>
</body>
</html>
